Research ArticleOncology
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Stephanie Robu, Margret Schottelius, Matthias Eiber, Tobias Maurer, Jürgen Gschwend, Markus Schwaiger and Hans-Jürgen Wester
Journal of Nuclear Medicine February 2017, 58 (2) 235-242; DOI: https://doi.org/10.2967/jnumed.116.178939
Stephanie Robu
1Chair of Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany
Margret Schottelius
1Chair of Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany
Matthias Eiber
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, München, Germany; and
Tobias Maurer
3Department of Urology, Klinikum Rechts der Isar, Technische Universität München, München, Germany
Jürgen Gschwend
3Department of Urology, Klinikum Rechts der Isar, Technische Universität München, München, Germany
Markus Schwaiger
2Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, München, Germany; and
Hans-Jürgen Wester
1Chair of Pharmaceutical Radiochemistry, Technische Universität München, Garching, Germany
Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 58, Issue 2
February 1, 2017
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Stephanie Robu, Margret Schottelius, Matthias Eiber, Tobias Maurer, Jürgen Gschwend, Markus Schwaiger, Hans-Jürgen Wester
Journal of Nuclear Medicine Feb 2017, 58 (2) 235-242; DOI: 10.2967/jnumed.116.178939
Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer
Stephanie Robu, Margret Schottelius, Matthias Eiber, Tobias Maurer, Jürgen Gschwend, Markus Schwaiger, Hans-Jürgen Wester
Journal of Nuclear Medicine Feb 2017, 58 (2) 235-242; DOI: 10.2967/jnumed.116.178939
Jump to section
Related Articles
Cited By...
- Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In {gamma}-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions
- Prostate-Specific Membrane Antigen-Targeted Radioguided Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients with a Suspicion of Locoregional Lymph Node Metastases: The DETECT Trial
- Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer
- A 2022 International Survey on the Status of Prostate Cancer Theranostics
- Occupational Radiation Exposure of Radiopharmacy, Nuclear Medicine, and Surgical Personnel During Use of [99mTc]Tc-PSMA-I&S for Prostate Cancer Surgery
- Radiation Dosimetry of 99mTc-PSMA I&S: A Single-Center Prospective Study
- Can Intraoperative Fluorescence Imaging Identify All Lesions While the Road Map Created by Preoperative Nuclear Imaging Is Masked?
- Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen: Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction
- Trending: Radioactive and Fluorescent Bimodal/Hybrid Tracers as Multiplexing Solutions for Surgical Guidance
- Prostate-Specific Membrane Antigen-Guided Surgery
- Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine
- Entering the Era of Molecularly Targeted Precision Surgery in Recurrent Prostate Cancer
- Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
- PSMA Ligands for PET Imaging of Prostate Cancer
- Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers
- Phase 2 Study of 99mTc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy